By Digifin Pty Ltd · About this coverage
Key Points
- Five-year Salix commercial agreement with Huntsville Hospital Health System
- Minimum contracted value US$0.5M for Salix Coronary Anatomy SaaS
- First SAPPHIRE Study participant converted to a commercial customer
- Deployment across HH Health 15-hospital network; fourth U.S. customer
- Plaque fee-per-scan and Flow (post FDA clearance) revenue not quantified
About Artrya (ASX:AYA)
Artrya Limited is an ASX-listed medical technology company founded in Perth in 2018. It builds software that reads coronary computed tomography angiography images and reports on coronary artery disease, including the extent of arterial plaque. Its buyers are hospital and health systems, and its commercial market is the United States.
Artrya (ASX:AYA) signed a five-year commercial agreement with Huntsville Hospital Health System for clinical use of its Salix platform, converting the first SAPPHIRE Study participant into a commercial customer and lifting its U.S. commercial customer count from three to four.
The agreement has a minimum contracted value of US$0.5M for Salix Coronary Anatomy under a recurring SaaS model, with additional fee-per-scan revenue from Salix Coronary Plaque and, once FDA cleared, Salix Coronary Flow. Salix is to be integrated into applicable clinical workflows across HH Health's 15-hospital network, which Artrya calls its largest U.S. customer deployment to date. HH Health joins Tanner Health, Northeast Georgia Health System and Cone Health. Full commercial terms are commercial in confidence; the five-year term is subject to customary termination and default provisions.
The release does not disclose fee-per-scan rates or expected total revenue beyond the US$0.5M Anatomy minimum.
Source: Artrya Limited (ASX:AYA), 2 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.